Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alpha Tau Medical Ltd.DRTS · Entity 4784 | Director | March 18, 2026 | March 18, 2026 |
| Lifeward Ltd.LFWD · Entity 7620 | Director | March 25, 2026 | March 27, 2026 |
| Nano Dimension Ltd.NNDM · Entity 5842 | Director | August 21, 2026 | August 25, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director · President and CEO | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alpha Tau Medical Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,986 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,986 |
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 7,767 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,767 F1: These ordinary shares represent the unvested portion of a grant of restricted share units, which vests in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service. |
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 4,680 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,680 F2: These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2035-05-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: These are options to acquire ordinary shares, which options will vest in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.41 · Expires 2036-03-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares represent the unvested portion of a grant of restricted share units, which vests in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.
F2: These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
F3: These are options to acquire ordinary shares, which options will vest in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.
F4: These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
Lifeward Ltd.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, no par value per shareSEC Table I · non-derivative | Direct | 7,657 |
Reported balance
After 2026-03-25 transaction · row 1
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 7,657 · Balance 7,657 F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date.
Nano Dimension Ltd.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Other · Disposed 10,000 · Balance 30,000 F1: The call option contracts (the "Options") was written before the Reporting Person became a Section 16 insider of the Issuer and therefore was reported on the Reporting Person's Form 3 filed with the Securities and Exchange Commission on August 25, 2026. The shares were sold in connection with the exercise of the Option by a third party. |
| Call options (obligation to sell)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2026-08-21 | Direct | 0 |
Reported balance
After 2026-08-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-21 · Other · Disposed 100 · Balance 0 F2: The Options were exercised in accordance with their terms, and no investment decision was made by the Reporting Person in connection therewith. The Options were exercisable at any time prior to the Expiration Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The call option contracts (the "Options") was written before the Reporting Person became a Section 16 insider of the Issuer and therefore was reported on the Reporting Person's Form 3 filed with the Securities and Exchange Commission on August 25, 2026. The shares were sold in connection with the exercise of the Option by a third party.
F2: The Options were exercised in accordance with their terms, and no investment decision was made by the Reporting Person in connection therewith. The Options were exercisable at any time prior to the Expiration Date.
ORAMED PHARMACEUTICALS INC.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,140,505 |
Ending reported balance
After 2026-09-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-24 · Grant · Acquired 349,497 · Balance 3,771,740 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. Row 2 · 2026-09-24 · Grant · Acquired 368,765 · Balance 4,140,505 F2: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2029-09-11 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-24 · Disposition to issuer · Disposed 196,500 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F3: The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2030-01-08 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-24 · Disposition to issuer · Disposed 190,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F4: The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2027-06-30 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-24 · Disposition to issuer · Disposed 49,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F5: The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-24 · Disposition to issuer · Disposed 97,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F6: The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F7: The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-24 · Disposition to issuer · Disposed 107,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F8: The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy wholly-owned corporation | 126,000 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 126,000 |
Filing footnotes · ownership attribution and instrument terms
F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
F2: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.
F3: The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.
F4: The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
F5: The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested.
F6: The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.
F7: The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
F8: The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 107,000 | Not disclosed Strike: $13.89 | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 9 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,000 shares Expires 2032-01-03 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F8 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $10.40 | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 8 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2031-02-03 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F7 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 97,000 | Not disclosed Strike: $8.14 | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 7 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,000 shares Expires 2028-01-31 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F6 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 49,000 | Not disclosed Strike: $7.77 | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 6 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires 2027-06-30 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F5 · derivative.exercise_date: The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 190,000 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 5 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires 2030-01-08 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F4 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 196,500 | Not disclosed Strike: $3.16 | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 4 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,500 shares Expires 2029-09-11 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F3 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 368,765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,140,505 F2 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 349,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103540 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,771,740 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 22:08 UTC | Nano Dimension Ltd. NNDM · Entity 5842 | OtherCall options (obligation to sell) · Derivative | 100 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001104659-26-100937 · tm2624005-2_4seq1.xml · derivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,000 shares Expires 2026-08-21 F2 · derivative.exercise_date: The Options were exercised in accordance with their terms, and no investment decision was made by the Reporting Person in connection therewith. The Options were exercisable at any time prior to the Expiration Date. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 22:08 UTC | Nano Dimension Ltd. NNDM · Entity 5842 | OtherOrdinary Shares | 10,000 | $1.50 | $15,000.00 |
DisclosureSEC source: 0001104659-26-100937 · tm2624005-2_4seq1.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The call option contracts (the "Options") was written before the Reporting Person became a Section 16 insider of the Issuer and therefore was reported on the Reporting Person's Form 3 filed with the Securities and Exchange Commission on August 25, 2026. The shares were sold in connection with the exercise of the Option by a third party. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 44,818 | $3.31 | $148,347.58 |
DisclosureSEC source: 0001213900-26-037447 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,422,243 F1 · shares: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share. F1 · price: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:38 UTC | Lifeward Ltd. LFWD · Entity 7620 | GrantOrdinary Shares, no par value per share | 7,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-001814 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,657 F1 · shares: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:46 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 167,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-031013 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,422,243 F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 20:06 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-028291 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,255,238 F1 · kind: This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionPerformance Stock Units · Derivative | 109,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009479 · ownership.xml · derivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 109,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009479 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,355,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantPerformance Stock Units · Derivative | 109,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001280 · ownership.xml · derivative · entry 4 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 327,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001280 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,246,238 F2 · shares: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. F2 · price: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 232,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001280 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,919,238 F1 · shares: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012239 · ownership.xml · nonDerivative · entry 3 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,686,598 F3 · shares: Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 186,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012239 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,586,598 F2 · shares: Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 141,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012239 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,400,598 F1 · shares: Represents shares issued on settlement of performance stock units ("PSUs") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 433,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-001168 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259,598 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 36,125 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-095931 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,826,098 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:41 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 329,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001151 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,781,098 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 27,417 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 120,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033145 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,452,098 F1 · price: Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 10:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 279,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024939 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,332,098 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 23,250 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| March 16, 2023 Filed Mar 16, 2023 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 26,000 | $2.04 | $53,014.00 |
DisclosureSEC source: 0001209191-23-019367 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wholly-owned corporation Disclosed balance after: 126,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:25 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 100,000 | $2.01 | $201,000.00 |
DisclosureSEC source: 0001209191-23-018956 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wholly-owned corporation Disclosed balance after: 100,000 Read SEC document |
| October 27, 2022 Filed Oct 29, 2022 01:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054879 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,098 F1 · price: This transaction represents a charitable donation effective October 27, 2022. This is not a market transaction, thus no price has been reported. No value was received for the donated shares. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 12,631 | $8.36 | $105,595.16 |
DisclosureSEC source: 0001209191-22-043768 · doc4.xml · nonDerivative · entry 3 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078,098 F3 · shares: Payment of tax liability by withholding securities related to the 34,000 shares of Common Stock granted on July 28, 2022. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 126,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043768 · doc4.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,090,729 F2 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 42,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 34,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043768 · doc4.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,729 F1 · price: Represents Common Stock granted by the Issuer that vested on August 1, 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:41 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy · Derivative | 107,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001213900-22-000818 · ownership.xml · derivative · entry 4 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2032-01-03 F4 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:41 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 63,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-000818 · ownership.xml · nonDerivative · entry 3 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,729 F3 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:41 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 48,752 | $13.89 | $677,165.28 |
DisclosureSEC source: 0001213900-22-000818 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,729 F2 · shares: Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:41 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-000818 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,481 F1 · price: Represents Common Stock granted by the Issuer that vested upon grant. Read SEC document |
| January 03, 2022 Filed Jan 12, 2022 01:30 UTC Amendment | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy · Derivative | 107,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001213900-22-001613 · ownership.xml · derivative · entry 4 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2032-01-03 F5 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| January 03, 2022 Filed Jan 12, 2022 01:30 UTC Amendment | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 63,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-001613 · ownership.xml · nonDerivative · entry 3 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,729 F3 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4 · balance_after: This amendment is being filed to correct an administrative error in the Form 4 filed by Mr. Kidron, which reported that 950,729 shares of common stock are beneficially owned by him following the reported transactions. Mr. Kidron beneficially owned 930,729 shares of common stock following the reported transactions. Read SEC document |
| January 03, 2022 Filed Jan 12, 2022 01:30 UTC Amendment | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 48,752 | $13.89 | $677,165.28 |
DisclosureSEC source: 0001213900-22-001613 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,729 F2 · shares: Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022. Read SEC document |
| January 03, 2022 Filed Jan 12, 2022 01:30 UTC Amendment | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-001613 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,481 F1 · price: Represents Common Stock granted by the Issuer that vested upon grant. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GiftCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-068231 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,481 F2 · price: This transaction represents a charitable donation effective December 30, 2021. This is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 31,728 | $12.98 | $411,829.44 |
DisclosureSEC source: 0001213900-21-068231 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,481 F1 · kind: Payment of tax liability by withholding securities incident to the vesting of the issued security. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 22:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GiftCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-063983 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 818,209 F1 · price: This transaction represents a charitable donation effective December 3, 2021. This is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:43 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-046407 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748,573 F1 · price: Restricted Stock Units ("RSUs") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis. Read SEC document |
| August 31, 2021 Filed Dec 7, 2021 21:30 UTC Amendment | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-063944 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838,209 F1 · price: Restricted Stock Units ("RSUs") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis. F2 · balance_after: This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 748,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 838,209 shares of common stock following the reported transaction. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 220,000 | $20.11 | $4,423,144.00 |
DisclosureSEC source: 0001213900-21-041711 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,573 F1 · date: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range. Read SEC document |
| August 09, 2021 Filed Dec 7, 2021 21:30 UTC Amendment | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 220,000 | $20.11 | $4,423,144.00 |
DisclosureSEC source: 0001213900-21-063945 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,209 F1 · date: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. F2 · price: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. F3 · balance_after: This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 648,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 738,209 shares of common stock following the reported transaction. Read SEC document |
| February 03, 2021 Filed Feb 8, 2021 22:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001213900-21-007499 · ownership.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-03 F1 · kind: The Stock Option will vest in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| January 08, 2020 Filed Jan 14, 2020 21:06 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001213900-20-000988 · ownership.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.